Goldman Sachs CEO David Solomon’s 2025 Pay Soars to $47 Million After Strong Deal-Making Year 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
Baidu Shares Surge After Official Launch of Advanced Ernie 5.0 AI Model 
Microsoft Restores Microsoft 365 Services After Widespread Outage 
FCC Chairman Raises Competition Concerns Over Netflix–Warner Bros. Discovery Deal 
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
Winter Storm Triggers Widespread Flight Cancellations Across U.S. as Airlines Urge Travelers to Rebook 
Apple China Holiday Sale Offers Discounts Up to 1,000 Yuan on Popular Devices 
Nintendo Stock Jumps as Switch 2 Becomes Best-Selling Console in the U.S. in 2025 
Intel Stock Slides Despite Earnings Beat as Weak Q1 Outlook Raises Concerns 
Elon Musk Shares Bold Vision for AI, Robots, and Space at Davos 
NTSB Opens Investigation Into Waymo Robotaxis After School Bus Safety Violations in Texas 
Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
U.S. Lawmakers Demand Scrutiny of TikTok-ByteDance Deal Amid National Security Concerns 
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut 
ByteDance Finalizes Majority U.S.-Owned TikTok Joint Venture to Avert American Ban 
SEC Drops Gemini Enforcement Case After Full Repayment to Earn Investors 
NEW YORK, May 09, 2017 -- Ohr Pharmaceutical, Inc. (NASDAQ:OHRP), a clinical-stage pharmaceutical company developing novel therapies for ophthalmic diseases, today announced that it will report financial results for its second fiscal quarter ended March 31, 2017 after the market close on Thursday, May 11, 2017. The Company will also hold a live investor conference call and webcast at 5:00pm Eastern Time.
| Conference Call & Webcast | |
| Thursday, May 11, 2017 at 5:00pm Eastern Time | |
| Domestic: | 877-407-0789 |
| International: | 201-689-8562 |
| Conference ID: | 13661723 |
| Webcast: | http://public.viavid.com/index.php?id=124321 |
| Replays – Available through May 25, 2017 | |
| Domestic: | 844-512-2921 |
| International: | 412-317-6671 |
| Conference ID: | 13661723 |
About Ohr Pharmaceutical, Inc.
Ohr Pharmaceutical, Inc. (OHRP) is an ophthalmology research and development company. The company's lead drug candidate, Squalamine lactate ophthalmic solution, 0.2% (also known as OHR-102), is currently being studied using an eye drop formulation in a clinical trial for the treatment of the wet form of age-related macular degeneration. In addition, Ohr has a sustained release micro fabricated micro-particle ocular drug delivery platform technology. Additional information on the company may be found at www.ohrpharmaceutical.com.
Contact: Ohr Pharmaceutical Inc. Investor Relations 888-388-2327 [email protected] LifeSci Advisors, LLC Michael Wood 646-597-6983 [email protected]
